Covid-19 roundup: Just how much is the ‘first wave’ market for Covid-19 vaccines worth? One top analyst sets the prize at $20B
Now that we’ve seen the US government ink contracts on 800 million doses of Covid-19 vaccine, Bernstein’s Ronny Gal is ready to do the math on exactly what the global market should look like in 2021.
And it isn’t cheap.
The 28 players now in the race to produce a Covid-19 vaccine to end the pandemic — with the spotlight falling on the top 6 US/European companies on the ladder — are likely competing for a slice of a $20 billion “first wave” market, writes Gal. And even if 40% of the contracted vaccine never arrives, the US should have a line on enough shots to protect 75% of the US population.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.